Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the development, production and commercialisation of 3SBio’s bispecific antibody ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Two lateral striatal subregions integrate the acquisition of stimulus-based decision-making in spatiotemporally and functionally different manners, challenging the prior model through a dominance ...

Order of July 8, 2025 Regarding the Acquisition of Jupiter Systems, LLC by Suirui International Co., Limited By the authority vested in me as President by the Constitution and the laws of the United ...

Mammoth’s most realistic trade acquisition in 2025 NHL offseason The Utah Mammoth have already made big moves this NHL offseason, but could make another one to improve their roster.

The acquisition, which CoreWeave said is expected to close in the fourth quarter, was an all-stock deal for about $9 billion.